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ABSTRACT
Background: The World Heart Federation has undertaken an initiative to develop a series of Roadmaps to
promote development of national policies and health systems approaches, and to identify potential
roadblocks on the road to effective prevention, detection, and management of cardiovascular disease in
low-and middle-income countries (LMICs) and develop strategies for overcoming these. This Roadmap
focuses on atrial ﬁbrillation (AF). AF is the most common, clinically signiﬁcant arrhythmia and, among
other clinical outcomes, is associated with increased risk of stroke.
Methods: Development of this Roadmap included a review of published guidelines and research papers, and
consultation with an expert committee comprising experts in clinical management of AF and health systems
research in LMICs. The Roadmap identiﬁes 1) key interventions for detection, diagnosis, and management of
AF; 2) gaps in implementation of these interventions (knowledge-practice gaps); 3) health system roadblocks
to implementation of AF interventions in LMICs; and 4) potential strategies for overcoming these.
Results: More research is needed on determinants and primary prevention of AF. Knowledge-practice gaps for
detection, diagnosis, and management of AF are present worldwide, but may be more prominent in LMICs.
Potential barriers to implementation of AF interventions include long distances to health facilities, shortage of
health care professionals with training in AF, including interpretation of ECG, unaffordability of oral
anticoagulants for patient households, reluctance on the part of physicians to initiate oral anticoagulant
(OAC) therapy, and lack of awareness of the importance of persistent adherence to OAC therapy. Potential
solutions include training of nonphysician health workers and pharmacists in pulse-taking, use of
telemedicine technologies to transmit electrocardiogram results, engagement of nonphysician health
workers in OAC therapy adherence support, and country-speciﬁc support and education programs for
noncardiologist health care professionals.
Conclusions: AF affects millions of people worldwide and, left untreated, increases the risk and severity of
stroke and heart failure. Although guidelines for the detection, diagnosis, and management of AF exist,
there are gaps in implementation of these guidelines globally, and in particular in LMICs. This Roadmap
identiﬁes some potential solutions that may improve AF outcomes in LMICs but require further evaluation
in these settings.
1. BACKGROUND AND AIM
It is now well known that the number of deaths from
noncommunicable diseases (NCDs) is increasing globally,
particularly in low- and middle-income countries (LMICs)
[1,2]. Many NCDs, including cardiovascular diseases
(CVDs) and related conditions, can be detected early and
treated with cost-effective interventions, thus preventing
costly hospitalizations and death. However, this requires
coordinated health system responses built around evidence-
based strategies. In many LMICs, health resources are
scarce, and identifying priority, cost-effective interventions
for CVD and related conditions is vital for planning effective
health system responses to these diseases.
The aim of the World Heart Federation (WHF)
Roadmap Initiative is to provide guidance on priority in-
terventions on a global level that can be adapted to regional
and national contexts. The initiative does so by focusing on
a few priority interventions for CVD and related conditions
that are: 1) supported by high-quality evidence of a
measurable reduction in CVD; 2) feasible in various
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country contexts; and 3) affordable and cost effective. The
WHF Roadmaps not only identify key interventions, but
also aim to document barriers to implementing these in-
terventions and to identify potential strategies for over-
coming them. Roadmaps for addressing gaps in secondary
prevention of CVD, tobacco control, and hypertension
have already been published and are in the implementation
phase. The focus of this WHF Roadmap is nonvalvular
atrial ﬁbrillation (AF), in particular the detection and
management of AF in LMICs using evidence-based drug
therapy to prevent stroke. Valvular AF is also an important
public health problem in LMICs, but is not addressed in
detail here. Although AF is the main focus of this Road-
map, much of the recommendations on treatment and
health system roadblocks can be applied to atrial ﬂutter as
well.
2. AF: EPIDEMIOLOGY AND BURDEN OF DISEASE
AF is the commonest clinically signiﬁcant arrhythmia [3].
A Roadmap that promotes national policies and health
systems approaches to the management of AF and provides
tools and solutions for adaptation at a regional and national
level is particularly timely. Between 1990 and 2013,
although the global prevalence rate of AF decreased
slightly, the overall number of AF cases increased, ac-
cording to the GBD (Global Burden of Disease) 2013 study
(Table 1) [4]. The morbidity burden associated with AF, as
measured by disability-adjusted life years (DALYs), also
increased. Estimates of the prevalence of AF, and DALYs
associated with AF, are likely to underestimate true burden
due to the high prevalence of asymptomatic AF [3]. AF is
also associated with high costs incurred by individuals,
health care systems, and economies [3,5e8]. Common
clinical outcomes associated with AF are outlined in Box 1
[9]. Among other clinical outcomes, AF is associated with
increased risk of stroke and is found in one-third of all
ischemic strokes [10].
Past GBD studies have also suggested that the burden of
AF varies among regions, with high-income countries
experiencing higher prevalence, incidence, DALYs, and
mortality associated with AF than do LMICs [3]. However,
estimates of the extent of this difference should be inter-
preted with caution, as the lower rates of AF documented in
developing countries may be related to weaker surveillance
systems and geographical disparity in published data [3].
Moreover, in countries at all levels of development, a sub-
stantial proportion of AF cases are asymptomatic [11],
making them more difﬁcult to detect without advanced
medical technology. Research from the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy) registry
also suggests that patients with AF in LMICs tend to be
younger, more likely to experience heart failure, and less
likely to be managed according to published AF guidelines
(i.e., patients with AF in LMICs show lower use of oral an-
ticoagulants [OACs] and lower time in therapeutic range)
[12].
Estimated differences in AF burden between developed
and developing countries should also be interpreted in
light of the risk factor proﬁle of this condition. Although
European ancestry has been identiﬁed as one risk factor for
AF (compared to African and Asian ancestry) [13,14], the
risk of AF mainly increases with age [15] and is higher
among those with CVD such as myocardial infarction and
CVD risk factors such as hypertension, diabetes mellitus,
obesity, smoking, and alcohol use [13,16e22]. As these
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Box 1. Common clinical outcomes as a consequence
of AF [9]
 Increased mortality
 Increased risk and severity of stroke
 Increased risk of hospitalization
 Reduction in quality of life
 Reduction of exercise capacity
 Increased risk of heart failure
AF, atrial ﬁbrillation.
TABLE 1. Global burden of AF in 1990 and 2013
Cases* (All Ages) Rate per 100,000 (Age Standardized)
Mean 95% UI Mean 95% UI
Global prevalence
Year
1990 6,841,147 6,602,764e7,114,686 213.7 205.9e222.6
2013 11,178,627 10,655,102e11,683,727 191.3 182.1e200.1
Global DALYs
Year Mean 95% UI Mean 95% UI
1990 854,714 693,332e1,049,075 26.7 21.7e32.7
2013 1,888,690 1,590,032e2,224,863 32.5 27.5e38.2
Data from GBD (Global Burden of Disease) 2013 study [4].
AF, atrial ﬁbrillation; DALYs, disability-adjusted life years; UI, uncertainty interval.
*Cases rounded to the nearest whole number.
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risk factors continue to increase in developing countries, so
likely will the burden of morbidity and mortality from AF.
This burden may be further compounded by the shortage
of health care resources in many developing countries, as
successful management of AF requires consistent and long-
term interaction between the patient and health care
system.
3. KEY INTERVENTIONS FOR DETECTION,
DIAGNOSIS AND MANAGEMENT OF AF
3.1. Primary prevention
As with all health conditions, primary prevention of AF
(i.e., reducing the risk of ﬁrst onset by targeting modiﬁable
risk factors) (Fig. 1) is the ultimate goal of the medical and
public health community, but is made challenging by
persistent gaps in knowledge regarding determinants of
AF. Models such as CHARGE-AF (Cohorts for Heart and
Aging Research in Genomic Epidemiology AF consortium)
score [23] have been developed to predict risk of AF, and
to identify patients who may beneﬁt from preventative
interventions, based on age, race, height, weight, blood
pressure, smoking, use of antihypertensive medication,
diabetes, and history of myocardial infarction and heart
failure. However, this model has only been validated for
populations in the United States and Western Europe [23].
Moreover, although the beneﬁts of interventions to manage
risk factors such as weight, blood pressure, smoking, and
diabetes for health outcomes generally are well established
and relevant to populations globally, primary prevention
trials for AF have yet to establish a role for interventions for
speciﬁc risk factors. There is an urgent need for research
that can inform primary prevention efforts for AF in more
geographically and racially diverse populations, while also
evaluating the effectiveness of preventative strategies aimed
at reducing the risk of AF globally [24].
3.2. Screening
Although a shortage of evidence of AF determinants and
prevention strategies restricts primary prevention efforts,
there is stronger evidence that early detection and treatment
can reduce morbidity and mortality due to AF. Guidelines
recommend that all patients who present with symptoms of
AF—breathlessness, palpitations, syncope, chest discom-
fort, or stroke—should have their pulse checked for irreg-
ularities as well as 12-lead electrocardiogram (ECG) [25].
Prolonged ECG monitoring may be especially useful in
patients with heart failure and post-stroke, to enhance
detection and reduce health resource utilization and costs,
depending on local resource and expertise. This strategy
should be complemented by screening for asymptomatic
AF. In a large randomized trial comparing routine practice
versus targeted population-based screening and opportu-
nistic screening, opportunistic palpation (pulse taking) of
patients 65 years of age and older, with or without known
AF risk factors (with follow-up ECG for those with an
irregular pulse), was found to be the cheapest and most
effective method of screening for AF (opportunistic
screening was found to detect similar numbers of new cases
compared with systematic screening [1.64% vs. 1.62%],
and requires fewer resources) [26]. One limitation of
opportunistic pulse palpation is the high number of false
positives that can result in unnecessary ECGs (although
unnecessary ECGs are not harmful per se, accurate inter-
pretation of ECGs can only be done by speciﬁcally trained
staff, of which there may be few in low-resource settings). A
recent meta-analysis has suggested that newer technologies
such as modiﬁed blood pressure monitors and single-lead
ECGs may be more accurate in detecting AF [27], and at-
home blood pressure monitors have been estimated to
reduce strokes and save costs by the UK National Institute
of Clinical Evaluation [28]. However, these technologies are
not widely available and therefore their use for large-scale
screening initiatives is not yet feasible.
3.3. Diagnosis
Although an irregular pulse may point to AF, an ECG is
still required to conﬁrm the diagnosis. A negative ECG
does not exclude the diagnosis of AF by pulse taking
because AF may be paroxysmal (transient). In patients with
suspected AF, diagnosis should be conﬁrmed using a
single-lead rhythm strip or 12-lead ECG documenting 30
seconds of AF [29,30]. A 12-lead ECG can detect other
abnormalities such as left ventricular hypertrophy,
ischemia, and other clinical features. At ﬁrst diagnosis, AF
can be classiﬁed as 1 of 4 types: paroxysmal (self-termi-
nating, usually within 48 hours), persistent (lasts longer
than 7 days), long-standing persistent (has lasted 1 year or
more), or permanent (when presence of arrhythmia is
accepted and no rhythm control [i.e., stabilizing sinus
rhythm] is attempted). Although paroxysmal AF is asso-
ciated with somewhat lesser risk of thromboembolism than
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Normal rhythm Symptomac AFAsymptomac AF Complicaons
Primary prevenon Screening/diagnosis Diagnosis/ Management
FIGURE 1. Stages of AF and intervention strategies. AF, atrial ﬁbrillation.
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nonparoxysmal AF [31], all types of AF are associated with
sufﬁciently increased risk of thromboembolism, especially
stroke [32], making detection of even paroxysmal AF
critical (for any pattern of AF, a prime determinant of risk
of thromboembolism and prognosis is the presence of CVD
comorbidities such as hypertension or diabetes [see
following paragraph]). If AF is not detected with single-
lead rhythm strip or 12-lead ECG, a 24-hour ambulatory
monitor (Holter) or other long-term ECG monitoring may
be necessary. Only a few studies exist comparing methods
and duration of ECG monitoring but prolonged moni-
toring has been recommended for highly symptomatic
patients, and those with cryptogenic stroke [9,33e36].
Inexpensive smartphone-based rhythm monitoring equip-
ment has potential applications in LMICs, but systems for
deployment and validation require further development
and investigation.
Presence of CVD and other risk factors affects the risk
of stroke and prognosis in patients with AF. Patients with
conﬁrmed AF should undergo a thorough clinical assess-
ment including an analysis of family history, risk factors
and concomitant disease, to assess stroke risk. The risk
factors for stroke among AF patients for which there is an
evidence base include prior stroke, transient ischemic
attack, thromboembolism, age, hypertension, diabetes and
structural heart disease [9,37,38]. One tool for evaluating
stroke risk among AF patients is the CHA2DS2-VASc score
[39]. The CHA2DS2-VASc is a point-based risk stratiﬁca-
tion system that assigns 2 points to a history of stroke,
transient ischemic attack, or thromboembolism and 75
years of age, and 1 point each to a history of congestive
heart failure, hypertension, diabetes, or vascular disease; 65
to 74 years of age; or female sex. OAC therapy is recom-
mended for those with a CHA2DS2-VASc score of 2 or
above [29]. In East Asian people, there is evidence that the
risk beneﬁt balance of anticoagulation may justify use of a
lower cutoff (e.g., CHA2DS2-VASc score of 1, younger age)
[40]. In addition to a thorough clinical examination, all
patients with AF should also undergo an echocardiogram
to assess for underlying heart disease that requires treat-
ment [9,25]. Heart failure was more common among in-
dividuals with AF in Africa than in other regions of the
world [12]. The absence of symptoms among patients
presenting with AF does not suggest lower risk of stroke
and these asymptomatic patients should also undergo
thorough clinical assessment [11,41,42].
3.4. Management
After clinical assessment of conﬁrmed AF cases and based
on stroke risk, anticoagulant therapy should be initiated to
reduce risk of stroke and systemic thromboembolism,
while also taking into account the risk of major bleeding
(discussed subsequently). Anticoagulation for medium-
VOL. -, NO. -, 2017
ISSN 2211-8160/$36.00.
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12-lead ECG to conﬁrm diagnosis if persistent or
permanent AF is suspected based on pulse palpaon
Assessment of stroke risk based on history of stroke and
concomitant condions (using CHA2DS2-VASc score)
Assessment and management of bleeding risk, and
iniaon of oral ancoagulaon to reduce stroke risk
Symptom alleviaon using rate and rhythm control
therapies
Follow up in primary health care to monitor stroke
risk, bleeding risk and other condions.
Pulse palpaon for paents presenng with
AF symptoms
Opportunisc screening of paents 65+ years
(pulse palpaon)
FIGURE 2. The ideal patient care pathway for AF patients. AF, atrial ﬁbrillation; CHA2DS2-VASc, congestive heart
failure, hypertension, age 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism,
vascular disease, age 65 to 74 years, sex category (female); ECG, electrocardiogram.
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and high-risk nonvalvular AF is identiﬁed as a recom-
mended policy option by the World Health Organization
(WHO) in the WHO Global Action Plan for the Prevention
and Control of NCDs 2013 to 2020 [43]. Until recently,
warfarin and other vitamin K antagonists were the only
class of OACs available, but since 2009 nonevitamin K
anticoagulants (NOACs) have been introduced that reduce
the need for frequent monitoring, and the side effects
associated with vitamin K antagonists are as effective as
warfarin in reducing stroke and may be associated with a
lower risk of bleeding [44]. Evidence suggests that NOACs
may be cost-effective options for stroke prevention in AF
patients [45], although possibly more so in settings with
poor warfarin management [46]. Nevertheless, warfarin
remains the most widely available anticoagulant and is the
only anticoagulant on the World Health Organization’s
Essential Medicines list [47]. Aspirin, which is widely used
as an antithrombotic therapy for AF is neither effective nor
safe and has been written out of most published guidelines
[48]. The combination of aspirin plus clopidogrel is more
effective than aspirin alone but less effective than warfarin
when the time in therapeutic range is reasonably well
managed, and has no advantage over warfarin in terms of
major bleeding [49,50].
The decision to initiate anticoagulant therapy to reduce
risk of stroke must be weighed against the risk of major
bleeding complications associated with anticoagulant
therapy, the most dangerous of which is intracerebral
hemorrhage [29,51]. Prior to initiating anticoagulant use,
risk of bleeding should be assessed. Assessment tools for
identifying risk factors for bleeding have been recom-
mended by some national guidelines in high-income
countries, including risk factors such as hypertension,
abnormal renal function, abnormal liver function, prior
stroke, prior major bleeding or predisposition to bleeding,
labile international normalized ratio (INR), 65 years of
age, prior alcohol or drug usage, and medication usage
predisposing to bleeding (e.g., antiplatelet agents, nonste-
roidal anti-inﬂammatory drugs) [29,52,53], but these tools
have not been validated in LMICs. Some research suggests
that those of Chinese ethnicity are more susceptible to
intracerebral hemorrhage than are those of European
TABLE 2. Roadblocks, strategies, and potential solutions for achieving effective AF management
Dimension Roadblock Strategy Potential Solutions
Geographic
accessibility
Long distances to clinics result in
low numbers of rural patients
presenting to clinics for
screening.
1. Improve accessibility of
screening for rural
populations.
2. Strengthen capacity for ECG
testing in remote areas.
1. Train community health workers or pharmacists to
screen for possible AF with pulse-checking in
nonclinic settings.
Educate at risk-populations (e.g., those 65þ years of
age) to self-screen with pulse checks.
2. Implement novel telemedicine technologies
(e.g., transmission of ECG results from rural areas
to urban facilities).
Availability Shortage of health care
professionals with training in
AF, including interpretation of
ECG, initiation of and
monitoring of anticoagulation
therapy.
1. Raise awareness of AF among
health care professionals.
2. Reduce dependence on high-
ly trained medical staff for AF
screening and
management.
1. Conduct awareness campaigns through health care
professional networks.
Improve postgraduate training and CME.
Develop simple and locally applicable AF guidelines.
2. Implement NPHW-managed anticoagulation
program.
Affordability OACs potentially unaffordable for
patient households, resulting
in nonadherence to treatment
regime.
1. Improve affordability of OACs. 1. Provide universal health care coverage for essential
medicines.
2. Implement internationally recognized policies for the
reduction of essential medicine costs (Box 2).
Acceptability Reluctance of physicians and
patients to initiate
anticoagulation therapy.
Lack of awareness of importance
of persistent adherence to
OAC therapy.
1. Improve awareness of and
capacity for managing
OAC therapy among
physicians.
2. Improve patient understand-
ing of importance of OAC
therapy and capacity to
adhere to therapy.
1. Conduct country-speciﬁc training on OAC therapy
management and support programs for
noncardiologist health care professionals.
2. Develop and implement country-speciﬁc patient
education, medical literacy, and support
programs for diagnosed AF patients on OAC
therapy.
3. Conduct research into feasibility of self-monitoring
programs for patients on OAC therapy in LMICs.
AF, atrial ﬁbrillation; CME, continuous medical education; ECG, electrocardiogram; LMICs, low- and middle-income countries; NPHW, nonphysician health worker; OAC, oral
anticoagulant.
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descent [54]. If bleeding risk factors are present with
increased bleeding risk, in general, anticoagulant therapy
should not be withheld, but regular review and attempts to
address bleeding risk factors are recommended [29].
Control of hypertension and avoidance of concomitant
antiplatelet therapy are among the more important strate-
gies to reduce the risk of major bleeding in anticoagulated
patients with AF.
Although anticoagulant therapy is the only proven way
to reduce stroke or systemic embolism among patients
with AF, arrhythmia management therapies may reduce AF
symptoms and improve patient quality of life [55]. The ﬁrst
aim of arrhythmia management is to slow the ventricular
rate to a resting rate of <100 beats/min. Initiation of drug
therapy to stabilize sinus rhythm (rhythm control) is based
on extent of symptoms and patient and physician values
and preferences, as currently there is no evidence that
rhythm control therapies reduce the risk of stroke [55].
After diagnosis and a treatment plan are established,
most patients with AF can be followed in primary health
care (PHC) to monitor heart rate and rhythm and to
reassess risk stratiﬁcation [25]. Monitoring of AF patients
in PHC also provides the opportunity to monitor and treat
comorbid cardiovascular conditions [56,57], in particular
hypertension, heart failure, diabetes, and valvular abnor-
malities. Conversely, in PHC, individuals presenting with
these conditions have a high prevalence of AF, which
should be borne in mind during their assessment.
Although valvular AF is not the focus of this Roadmap,
management of AF should include consideration of the
management of rheumatic heart disease (RHD) and
valvular heart disease, as these diseases are common in
LMICs and a large proportion of those suffering from them
(30% to 40%) develop AF [58]. Further guidance on
management of and health system responses to RHD is
included in the WHF RHD Roadmap.
3.5. The “ideal” patient care pathway
for AF patients
Based on the evidence cited previously, Figure 2 outlines key
recommendations for detection, diagnosis and management
of AF, or the “ideal patient pathway” for AF patients. This
includes: 1) screening of individuals with known AF risk
factors and opportunistic screening of patients 65 years of
age or older coming in for review; 2) 12-lead ECG to conﬁrm
suspected persistent or permanent AF; 3) assessment of
stroke risk; and 4) initiation of anticoagulant therapy,
combined with lifestyle modiﬁcation advice if appropriate
(e.g., weight reduction, smoking cessation). Although rate
and rhythm control are important steps for management of
symptoms, they are included in a different color, as this
pathway is intended to outline only the bare minimum
evidence-based interventions for reducing mortality associ-
ated with AF. However, it should be noted that several other
opportunities to change prognosis in AF exist (e.g., pre-
vention and management of tachycardiomyopathy).
4. KNOWLEDGE-PRACTICE GAPS
Despite evidence supporting opportunistic pulse palpation
of patients 65 years of age and older, with conﬁrmatory
diagnosis using 12-lead ECG [26], the pulse is not routinely
palpated in individuals older than 65 years of age. It should
be noted that the basis of this pragmatic recommendation is
a single randomized controlled trial in a high-income
country where cardiology review was widely available,
and therefore more context-speciﬁc research from LMICs is
needed. Also despite guideline-recommended prevention of
stroke with anticoagulant therapy [29], large gaps in
implementation of this therapy remain [10]. These
knowledge-practice gaps are present worldwide. The
GARFIELD (Global anticoagulant registry in the ﬁeld) reg-
istry, a study of 19 countries in 2009 to 2011, revealed that
38.0% of patients with high risk of stroke had not received
anticoagulant therapy, whereas 42.5% of those at low risk
(score 0) did [59]. The PINNACLE (Practice Innovation and
Clinical Excellence) study in the United States found that
less than half of high-risk patients were receiving OAC
therapy [60]. In the EORP-AF (EURObservational Research
Programme-Atrial Fibrillation) general registry of 9 Euro-
pean countries, while use of OACs was higher (approxi-
mately 81% to 81% of high stroke risk patients), persistence
of therapy was still not optimal (84% of those prescribed
with vitamin K antagonist remained on therapy 1 year
later), and despite guidelines, antiplatelet therapy
(commonly aspirin) was used in 15% of low risk patients
and in 31% of high-risk patients [61].
Although present worldwide [61,62], these gaps vary in
degree across countries, appearing to be most prominent in
LMICs. Data fromLMICs are scarce butwhat does exist points
to very low rates of oral anticoagulation therapy among AF
patients [12,24,63]. A review of existing literature [63] found
that estimated rates of anticoagulant use range fromonly 2.7%
to 50% in China [63e65], 26% to 44% in Pakistan [66], 16%
in Malaysia [67], from 46.7% to 57.8% in Brazil [68], 36.8%
inMexico [69], 72.7% in Argentina [70], 33% in South Africa
[71], 34.2% in Cameroon [72], from 11.5% (rural) to 26.5%
(urban) in Zimbabwe [73], 62% in Senegal [74], from 30.1%
to 67.3% in Turkey [75,76], 13% to 53.9% in Serbia [77],
27% in Kosovo [78], and 7.1% in Moldova [79]. The Gulf
SAFE (Gulf Survey of Atrial Fibrillation Events) registry
revealed similarly low rates of anticoagulation use (49% of
patients) in 6 Gulf countries (Bahrain, Kuwait, Oman, Qatar,
United Arab Emirates, and Yemen) [80].
Most evidence on AF knowledge-practice gaps in
LMICs focuses on gaps in management of stroke risk
among AF patients with OACs. However, there is evidence
of gaps across the continuum of care for AF globally, which
are likely to apply in LMICs. For example, research in
Canada suggested that noncardiologist physicians lack
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sufﬁcient knowledge, skills and conﬁdence to diagnose AF,
with diagnosis of paroxysmal or asymptomatic AF being
particularly challenging, and that continuous professional
education and development is necessary to strengthen the
capacity of physicians to navigate AF screening and diag-
nosis guidelines [81].
5. ROADBLOCKS AND SOLUTIONS
Table 2 identiﬁes potential roadblocks along the ideal
patient pathway for AF screening, diagnosis, and man-
agement. Potential roadblocks and solutions were identi-
ﬁed through a review of published literature as well as
through consultation with an expert committee, comprised
of experts in AF clinical management and health systems
research in LMICs. These roadblocks are presented in
terms of barriers to geographical accessibility, availability,
affordability and acceptability of AF health care, drawing
on existing frameworks for identifying health systems
barriers in LMICs [82e84]. Also outlined are strategies for
addressing these roadblocks and speciﬁc potential solu-
tions for executing these strategies.
5.1. Improving accessibility and availability of
screening for rural populations
This Roadmap recommends that screening for AF is best
conducted via opportunistic palpation (pulse taking) of
patients 65 years of age and older, with or without known
AF risk factors, with follow-up ECG for those with an
irregular pulse. Following this recommendation may be
challenging, however, in remote settings in LMICs. In these
settings, when at-risk individuals present at clinics, health
professionals who are trained in interpretation of ECGs may
not always be available. This may make the diagnosis of
paroxysmal AF particularly difﬁcult as it would require
multiple ECG measurements to detect. Novel technologies
that allow for cardiac rhythm assessment by nonspecialist
health care workers may reduce the dependence on spe-
cialists for AF screening [85]. These include approaches for
measuring pulse irregularity with inexpensive tools such as
oscillometric blood pressure devices [86], smartphones
[87,88], or handheld ECG devices that facilitate multiple
ECG measurements [87,88]. As mentioned previously,
however, these technologies are not yet readily available in
LMICs; they have not been tested in these settings and the
training and support required to implement them effectively
must be considered [85]. New research on the feasibility of
a nonphysician health worker (NPHW)eled screening AF
program in community health centers in China is planned
and will offer valuable evidence of the effectiveness of such
programs. In the meantime, experiences in successful
training of NPHWs to screen for CVD [89,90] and cancer
Box 2. Strategies for improving the affordability of
CVD medications [102]
1. Provide free essential drugs through universal
health coverage.
2. Increase the efﬁciency of the medication supply
chain to promote access to medicines within
existing health budgets (through more efﬁcient
selection, quantiﬁcation and forecasting, procure-
ment, storage, and distribution of medications).
3. Promote the use of high-quality, safe, and
efﬁcacious generic medications by overcoming
legal barriers relating to patents and licenses in
LMICs.
4. Develop policies to reduce end-user prices,
including regulating retail mark-ups and
eliminating tariffs on medicines.
5. Engage the pharmaceutical industry to price CVD
medicines at affordable levels in LMICs.
CVD, cardiovascular disease; LMICs, low- and middle-income
countries.
Box 3. The IMPACT-AF trial in India
The IMPACT-AF trial is testing the effectiveness of a
comprehensive customized intervention for
increasing the rate and persistence of use of OACs in
patients with AF in 5 LMICs. In India the intervention
will involve training nonphysician health workers to
educate patients in: 1) AF, stroke, and recognizing
the symptoms of a stroke; 2) the importance of OACs
to prevent stroke, and precautions to be taken while
on warfarin therapy (as most Indian AF patients are
on warfarin); and 3) the importance of medication
adherence, identifying barriers in nonadherent
patients, and providing strategies to overcome those
barriers. Diaries are given to patients to allow them
to record days when they take medications, and
included educational content. NPHWs are trained to
follow-up patients, monitor international normalized
ratio, identify nonadherent patients and barriers to
treatment adherence, and support the patient
toward getting back on treatment. The intervention
also includes an educational intervention for
physicians hosted at Duke University, consisting of
webinars and access to guidelines on the use of
OACs in AF.
AF, atrial ﬁbrillation; IMPACT-AF, Integrated Management Program
Advancing Community Treatment of Atrial Fibrillation; LMICs, low-
and middle-income countries; OACs, oral anticoagulants.
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[91] in LMICs may provide useful insights for imple-
mentation of nonspecialist screening programs for AF.
The ﬁeld of telemedicine may also provide opportu-
nities for addressing trained health care professional
shortages in LMICs [92,93], with some ﬁndings suggesting
that transmission of ECG results from remote, rural areas
to urban facilities may improve detection of CVD generally
[94]. However, the effectiveness and cost effectiveness of
telemedicine in LMICs generally [93e95], and speciﬁcally
for detection of AF, has not been sufﬁciently evaluated and
requires further research. Any strategies that make use of
novel technologies for detection of AF will only be effective
in reducing mortality associated with AF if OAC treatment
is also available and affordable to those with diagnosed AF,
and if structures are in place for the successful management
of OAC therapy.
5.2. Improving the affordability of OACs
Any effort to reduce mortality associated with AF will only
succeed if drug treatment, whether warfarin or NOACs, is
readily available to those who need it, without causing
undue ﬁnancial hardship [43]. The affordability of
warfarin speciﬁcally has not been studied, but evidence of
a link between poor adherence to OACs and poverty
[96,97], of the unaffordability of other CVD medications
in LMICs [98] and the of catastrophic impact of health
care costs for CVD generally [99,100] may provide some
indication of the likely burden that most chronic CVD
medication costs impose on patient households.
Currently, the affordability of NOACs in LMICs in
uncertain [101], and research on the cost effectiveness of
these drugs in these settings is needed. The WHF Road-
map for secondary prevention of CVD [57] identiﬁed
strategies that have been previously recommended to in-
crease the affordability of CVD medications [102] and
NCD medications generally [103]. These strategies are
relevant to OAC drug therapies (Box 2).
5.3. Reducing dependence on highly trained
medical staff for AF management
Dependence on medical specialists for AF treatment man-
agement can be challenging in LMIC settings that suffer
from a shortage of highly trained medical professionals.
Research from the United Kingdom and the Netherlands
has suggested that nurse-led management of AF treatment,
with the use of computerized decision support systems and
near-patient testing in a primary-care setting, can be an
effective [104] and cost-effective [105] alternative to
hospital-based management. Novel interventions for
improving management of AF by family physicians in
LMICs supported by NPHWs are currently being studied
(Box 3) and the results will provide valuable insights for
how to increase the role of family physicians and NPHWs
across the AF patient treatment pathway.
5.4. Improving capacity for management of OAC
therapy among patients
Successful management of stroke risk with OAC therapy
among AF patients requires maintenance of INR within a
target therapeutic range through regular monitoring and
dose adjustments. Over- or undercoagulation can result in
thrombotic or hemorrhagic events [106]. The risks asso-
ciated with OAC therapy are an important factor in
physician and patient preferences regarding initiation of
OAC [107], and perhaps even more likely so in LMIC
contexts where regular visits to a physician may be difﬁcult
due to travel distances, long wait times, or high out-of-
pocket costs [43,84,108]. Research from high-income
countries has suggested that self-management of OAC
therapy among AF patients, with appropriate support and
education, may be at least as effective as physician moni-
toring in reducing risk of thromboembolism [109], and
possibly more cost effective [110]. Self-monitoring requires
the patient measure the INR using a point-of-care device
Box 4. Examples of international AF registries
[12,59,61,80,112]
RE-LY registry: 47 countries across all world regions
Garﬁeld-AF registry: 19 countries worldwide with
34 total planned
EORP-AF European registry: 9 European Society of
Cardiology member countries
Gulf SAFE registry: 6 Middle Eastern Gulf countries
J-TRACE: Japan Thrombosis Registry for atrial
ﬁbrillation, coronary, or cerebrovascular events
AF, atrial ﬁbrillation.
FIGURE 3. Adapting the WHF Roadmaps at the national
level. Reproduced with permission from Perel et al. [113].
CVD, cardiovascular disease; WHF, World Heart
Federation.
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and self-adjust, if necessary, their dose of warfarin using a
nomogram (dose prediction chart) [110,111]. However,
evidence surrounding self-monitoring of OAC among AF
patients and the necessary elements for success of such
interventions remains limited, and what exists has focused
on high-income countries alone. Further research is
required on the potential for patient self-monitoring of
OAC therapy as a means of reducing risk of thrombotic or
hemorrhagic events in LMICs. Such research should be
interpreted in light of different contextual factors, in
particular that of the likely increase of the availability and
affordability of NOACs in LMICs, which reduce the need
for improved INR monitoring.
5.5. Strengthening health information systems
As noted previously, there is a paucity of data on the
incidence and quality of care of individuals with AF
globally, and in particular in LMICs. Without this infor-
mation, resource allocation for the solutions proposed here
or other strategies to improve AF detection, diagnosis, and
treatment in any country is unlikely to be evidence-based
and efﬁcient. In order to support the planning and moni-
toring of AF interventions, health information systems
must be developed. These should be simple, representa-
tive, context appropriate, and timely, and be established as
part of a larger NCD surveillance strategy. Some existing
AF registries are identiﬁed in Box 4. Further guidance on
the development of health information systems for high-
and middle-income countries (e.g., national or regional
registries and electronic health records) as well as low-
income countries (e.g., periodic representative surveys), is
provided in the WHF Roadmap on secondary prevention
of CVD [57].
6. ADAPTING THE AF ROADMAP TO REGIONAL
AND NATIONAL CONTEXTS
The AF and other WHF Roadmaps provide general guid-
ance on screening, diagnosis, and management of AF;
identify roadblocks to implementing evidence-based
approaches in LMICs; and suggest potential strategies to
overcoming these. The application of these strategies to
speciﬁc contexts must be considered further to adapt
region- or country-speciﬁc Roadmaps. The WHF has
described the process of producing region- and country-
speciﬁc Roadmaps [113].
National roadmaps should be developed within mul-
tisectoral partnerships, including intergovernmental orga-
nizations, heart health advocacy foundations,
cardiovascular scientiﬁc organizations, healthcare leaders,
providers from primary and specialized care, private-sector
stakeholders, and people affected by CVD (including pa-
tients and caregivers). To be successful, they will also
require effective advocacy toward policy makers and poli-
ticians in national governments.
The necessary steps for adapting the WHF AF Road-
map at the national level include (Fig. 3):
1. Develop and convene a multisectoral coalition to adapt
the global Roadmap to local circumstances.
2. Conduct a situation analysis of the health system for AF,
including epidemiologic proﬁling, relevant policies, and
assets.
3. Conduct policy dialogues with multiple local stake-
holders. Local problems, speciﬁc barriers, and potential
solutions should be discussed and appropriate strategies
selected according to context.
4. Develop a plan to evaluate the implementation of the
selected strategies.
7. CONCLUSION
AF affects millions of people worldwide and, left untreated,
increases the risk and severity of stroke and heart failure.
Although guidelines for the screening, diagnosis, and
management of AF exist, there are gaps in implementation
of these guidelines globally, and in particular in LMICs.
Long distances to health facilities, a shortage of trained
health professionals, and low awareness of and adherence
to OAC treatment among health professionals and patients
may all serve as roadblocks to guideline adherence. This
Roadmap identiﬁes some potential solutions, such as
NPHW-led AF screening programs, the use of novel tele-
medicine technologies and OAC education interventions,
all of which may be feasible strategies for improving AF
outcomes in low-resource settings. It also highlights areas
where more research is needed, for example on de-
terminants and primary prevention of AF, the cost effec-
tiveness of novel technologies and telemedicine for
screening and diagnosis of AF in LMICs, gaps in manage-
ment of AF in LMICs and the feasibility of NPHW-led
interventions to improve AF management in these con-
texts. Although this Roadmap can serve as guidance on
potential strategies for improved AF screening, diagnosis,
and management in LMICs, the applicability of these
strategies to speciﬁc LMIC settings must be considered
further.
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